TW304941B - - Google Patents

Download PDF

Info

Publication number
TW304941B
TW304941B TW084110874A TW84110874A TW304941B TW 304941 B TW304941 B TW 304941B TW 084110874 A TW084110874 A TW 084110874A TW 84110874 A TW84110874 A TW 84110874A TW 304941 B TW304941 B TW 304941B
Authority
TW
Taiwan
Prior art keywords
substituted
alkyl
group
compound
phenyl
Prior art date
Application number
TW084110874A
Other languages
English (en)
Chinese (zh)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of TW304941B publication Critical patent/TW304941B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/42—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4
    • C07D311/56—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 without hydrogen atoms in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/12—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings
    • C07C39/14—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings with at least one hydroxy group on a condensed ring system containing two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
TW084110874A 1994-10-13 1995-10-13 TW304941B (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32287694A 1994-10-13 1994-10-13

Publications (1)

Publication Number Publication Date
TW304941B true TW304941B (enExample) 1997-05-11

Family

ID=23256829

Family Applications (1)

Application Number Title Priority Date Filing Date
TW084110874A TW304941B (enExample) 1994-10-13 1995-10-13

Country Status (23)

Country Link
US (2) US6051601A (enExample)
EP (1) EP0785930A1 (enExample)
JP (1) JP2983295B2 (enExample)
KR (1) KR100232341B1 (enExample)
CN (1) CN1160399A (enExample)
AU (1) AU696890B2 (enExample)
BR (1) BR9504385A (enExample)
CA (1) CA2201742A1 (enExample)
CO (1) CO4480024A1 (enExample)
CZ (1) CZ111797A3 (enExample)
FI (1) FI971524A7 (enExample)
HU (1) HUT77515A (enExample)
IL (1) IL115529A0 (enExample)
MX (1) MX9702731A (enExample)
NO (1) NO971672L (enExample)
NZ (1) NZ285156A (enExample)
PE (1) PE10897A1 (enExample)
PL (1) PL319688A1 (enExample)
RU (1) RU2128655C1 (enExample)
TR (1) TR199501270A2 (enExample)
TW (1) TW304941B (enExample)
WO (1) WO1996011920A1 (enExample)
ZA (1) ZA958597B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199900592T2 (xx) * 1996-09-16 1999-06-21 Pfizer Inc. Kromanol t�revlerinin haz�rland��� i�lem ve ara ba�lar
US5817684A (en) * 1996-12-13 1998-10-06 Eli Lilly And Company Leukotriene antagonists for use in the treatment or inhibition of cerebral focal stroke
IL128731A0 (en) * 1998-03-12 2000-01-31 Pfizer Prod Inc Method of preventing allograft rejection
EP0963755A3 (en) * 1998-04-16 2001-03-14 Pfizer Products Inc. Use of benzopyranes for preventing allograft rejection
SE0004245D0 (sv) 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use
WO2002060888A1 (en) * 2001-01-30 2002-08-08 Pfizer Products Inc. Processes for preparing chromanylbenzoic acids
AU4239302A (en) * 2001-06-28 2003-01-02 Pfizer Products Inc. Benzoic acid substituted benzopyrans for the treatment of atherosclerosis
JP4460450B2 (ja) 2002-06-19 2010-05-12 ビオヴィトルム・アクチボラゲット（プブリクト） 新規化合物、その使用および製造法
CA2574627A1 (en) * 2004-07-22 2006-02-02 Pharmacia Corporation Compositions for treatment of inflammation and pain using a combination of a cox-2 selective inhibitor and a ltb4 receptor antagonist
US7674822B2 (en) 2004-11-24 2010-03-09 Wyeth PTP1b inhibitors
AU2005316739A1 (en) 2004-12-13 2006-06-22 Galileo Pharmaceuticals, Inc. Spiro derivatives as lipoxygenase inhibitors
AU2005328328A1 (en) 2005-02-25 2006-09-08 Galileo Pharmaceuticals, Inc. Spiro-heterocyclic chromans, thiochromans and dihydroquinolines
US7842713B2 (en) * 2006-04-20 2010-11-30 Pfizer Inc Fused phenyl amido heterocyclic compounds
US7749995B2 (en) 2006-05-11 2010-07-06 Janssen Pharmaceutica Nv 3,4-dihydro-2h-benzo[1,4]oxazine and thiazine derivatives as CETP inhibitors
EP2034998A1 (en) 2006-05-11 2009-03-18 Janssen Pharmaceutica, N.V. 1,2,3,4-tetrahydro-quinoline derivatives as cetp inhibitors
AU2009290474A1 (en) 2008-09-11 2010-03-18 Pfizer Inc. Heteroaryls amide derivatives and their use as glucokinase activators
EP2604604A1 (en) * 2009-03-11 2013-06-19 Pfizer Inc Benzofuranyl derivatives used as glucokinase inhibitors
CA2864331C (en) 2012-02-14 2018-10-09 Children's Hospital Medical Center Use of small molecule inhibitors targeting the interaction between rac gtpase and p67(phox)
CN102920692A (zh) * 2012-10-25 2013-02-13 中国人民解放军第二军医大学 (e)-2-(1-羟基-4-环己酮)乙基咖啡酸酯在制备防治类风湿关节炎的药物中的应用
US9745253B2 (en) 2015-03-13 2017-08-29 Forma Therapeutics, Inc. Alpha-cinnamide compounds and compositions as HDAC8 inhibitors
AR105911A1 (es) 2015-09-03 2017-11-22 Forma Therapeutics Inc Inhibidores de hdac8 bicíclicos fusionados [6,6]
EP3383388B1 (en) 2015-11-30 2021-04-14 Merck Sharp & Dohme Corp. Aryl acylsulfonamides as blt1 antagonists
EP3383869B1 (en) 2015-11-30 2023-06-28 Merck Sharp & Dohme LLC Aryl sulfonamides as blt1 antagonists
US10370368B2 (en) 2015-11-30 2019-08-06 Merck Sharp & Dohme Corp. Aryl acylsulfonamides as BLT1 antagonists
EP3383868B1 (en) * 2015-11-30 2022-10-05 Merck Sharp & Dohme LLC Aryl sulfonamides as blt1 antagonists
US20190216790A1 (en) * 2016-10-13 2019-07-18 The Regents Of The University Of California Methods for Treating Pruritis
CN119700747B (zh) * 2025-02-26 2025-05-06 云南农业大学 苦杏碱醇a在制备防治骨质疏松症产品中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU469247A3 (ru) * 1972-01-14 1975-04-30 Майлз Лабораториз Инк (Фирма) Способ получени производных хромона
US4565882A (en) * 1984-01-06 1986-01-21 G. D. Searle & Co. Substituted dihydrobenzopyran-2-carboxylates
CA1320490C (en) * 1987-01-12 1993-07-20 Darrel M. Gapinski Anti-inflammatory agents
US4889871A (en) * 1987-05-29 1989-12-26 G. D. Searle & Co. Alkoxy-substituted dihydrobenzopyran-2-carboxylate derivatives
CA2019335C (en) * 1989-06-27 2000-08-01 Mitoshi Konno Phenylalkan (en)oic acids
US4996230A (en) * 1990-02-16 1991-02-26 Eli Lilly And Company Leukotriene antagonists
US5073562A (en) * 1990-05-10 1991-12-17 G. D. Searle & Co. Alkoxy-substituted dihydrobenzopyran-2-carboxylic acids and derivatives thereof
US5051438A (en) * 1990-05-16 1991-09-24 G. D. Searle & Co. Alkoxy-substituted dihydrobenzopyran-2-carboxylic acids and derivatives thereof, compositions and use
US5124350A (en) * 1990-06-28 1992-06-23 G. D. Searle & Co. Leukotriene b4 antagonists
EP0623122B1 (en) 1992-01-23 1997-03-05 Pfizer Inc. Benzopyran and related LTB4-antagonists.
MX9300312A (es) * 1992-01-23 1993-07-31 Pfizer Antagonistas benzopiranicos y relacionado de ltb.

Also Published As

Publication number Publication date
KR100232341B1 (ko) 2000-07-01
MX9702731A (es) 1997-06-28
TR199501270A2 (tr) 1996-06-21
IL115529A0 (en) 1996-01-19
NZ285156A (en) 1999-01-28
NO971672L (no) 1997-06-11
CO4480024A1 (es) 1997-07-09
EP0785930A1 (en) 1997-07-30
KR970706270A (ko) 1997-11-03
FI971524A0 (fi) 1997-04-11
AU2416795A (en) 1996-05-06
CZ111797A3 (cs) 1998-07-15
US6051601A (en) 2000-04-18
ZA958597B (en) 1997-04-14
HUT77515A (hu) 1998-05-28
CA2201742A1 (en) 1996-04-25
CN1160399A (zh) 1997-09-24
NO971672D0 (no) 1997-04-11
FI971524A7 (fi) 1997-04-11
JPH09512035A (ja) 1997-12-02
PL319688A1 (en) 1997-08-18
BR9504385A (pt) 1997-05-27
JP2983295B2 (ja) 1999-11-29
RU2128655C1 (ru) 1999-04-10
WO1996011920A1 (en) 1996-04-25
AU696890B2 (en) 1998-09-24
PE10897A1 (es) 1997-04-21
US6133286A (en) 2000-10-17

Similar Documents

Publication Publication Date Title
TW304941B (enExample)
EP0420511B1 (en) Heterocyclic derivatives
AP385A (en) Benzopyrans and related LTB4 antagonists.
IE58334B1 (en) Antiviral guanine derivatives
JPH055824B2 (enExample)
WO2007091570A1 (ja) スフィンゴシン－１－リン酸結合阻害物質
TW303364B (enExample)
CN106279095A (zh) 一种替格瑞洛关键中间体的制备方法
JP2765757B2 (ja) ベンゾピラン及び関連のｌｔｂ▲下４▼アンタゴニスト
WO1995005374A1 (en) Fused heteroaromatic cyclopentene derivative having endothelin-antagonist activity
HK1000245B (en) Benzopyran and related ltb4-antagonists
JPH02288845A (ja) ナフタレン誘導体の製法及びその合成中間体
CN101180284B (zh) 从四氢吡喃-3-酮制备四氢吡喃的方法
JPH0118899B2 (enExample)
TW200418838A (en) Compounds for the treatment of premature ejaculation
JP5492786B2 (ja) ゼラレノンマクロライドアナログを作製するための中間体および方法
JP2002530394A (ja) 新規アガロフラン誘導体、それらの製造、それらを含む医薬組成物および医薬としてのそれらの使用
JP3350778B2 (ja) ３−ヒドロキシオキセタンの製造方法
ZA200404392B (en) Preparation of cis-fused 3,3a,8,12b-tetrahydro-2H-dibenzo Ä3,4:6,7ÜcycloheptaÄ1,2-bÜfuran derivatives.
JP2739866B2 (ja) サイシンｎ誘導体
WO2007049813A1 (ja) ベンゾ［ｂ］チオフェン誘導体およびその製造方法
WO1995029906A1 (en) Benzofuran derivative and use thereof
JP3422512B2 (ja) 置換イミダゾピリダジン誘導体、その製造法、中間体および剤
KR0165626B1 (ko) 칼륨 채널 개방제로서의 벤조피란
KR100237527B1 (ko) 류코트리엔 비4 길항물질로서의 벤조피란 및 벤조-축합된 화합물